

Susanne Malander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4339293/publications.pdf>

Version: 2024-02-01

20
papers

638
citations

933447

10
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

1342
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC). <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1235-1243.	1.7	4
2	Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 2541-2551.	1.1	3
3	Ovarian tumor frozen section, a multidisciplinary affair. <i>Acta Oncologica</i> , 2022, 61, 785-792.	1.8	4
4	Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesigned abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study. <i>BMC Cancer</i> , 2021, 21, 465.	2.6	1
5	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. <i>Genes</i> , 2021, 12, 742.	2.4	6
6	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 860-868.	1.4	4
7	SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1805094.	0.7	7
8	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 83-91.	2.8	41
9	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. <i>PLoS ONE</i> , 2020, 15, e0240418.	2.5	15
10	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1836-1850.	3.8	42
11	Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. <i>Scientific Reports</i> , 2019, 9, 15506.	3.3	10
12	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. <i>Lancet Oncology</i> , The, 2019, 20, 1409-1419.	10.7	179
13	Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 320-325.	1.8	0
14	Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. <i>Cell Reports</i> , 2018, 23, 2819-2831.e5.	6.4	36
15	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2018, 19, 1117-1125.	10.7	95
16	Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2017, 7, 109.	2.8	20
17	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015, 8, 424-433.	3.7	27
18	Independent review of AGO-OVAR 12, a GCI/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE, 2014, 9, e107643.	2.5	17
20	The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecologic Oncology, 2006, 101, 238-243.	1.4	125